Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Chun-Han Cheng, Department of Medical Education, Linkou Chang Gung Memorial Hospital, Taoyuan City 33305, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, New Taipei 23561, Taiwan
Wen-Rui Hao, Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 11002, Taiwan
Tzu-Hurng Cheng, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, Taichung 404328, Taiwan
Co-first authors: Chun-Han Cheng and Wen-Rui Hao.
Author contributions: All authors have made significant contributions to this editorial. Cheng CH and Hao WR contributed equally as co-first authors, jointly responsible for the conceptualization and initial drafting of the manuscript. Cheng CH focused on synthesizing the literature on SGLT2 inhibitors and their impact on myocardial function, while Hao WR provided clinical insights and critically assessed the therapeutic implications for diabetic cardiomyopathy; Cheng TH supervised the overall development and progression of the editorial, offering substantial input on revisions, particularly in the discussion of molecular mechanisms and potential clinical applications; Cheng TH also provided critical guidance on refining the manuscript's structure and flow to ensure clarity and coherence. All authors contributed to the final content by revising the manuscript for intellectual content and accuracy. They have all reviewed and approved the final version, ensuring that it meets the journal’s requirements.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to this manuscript. All authors have reviewed and approved the final version of the manuscript, and no financial or personal relationships exist that could have inappropriately influenced the research and findings presented in this paper.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tzu-Hurng Cheng, PhD, Professor, Department of Biochemistry, School of Medicine, College of Medicine, China Medical University, No. 91 Xueshi Road, North District, Taichung 404328, Taiwan. thcheng@mail.cmu.edu.tw
Received: August 10, 2024 Revised: November 1, 2024 Accepted: November 19, 2024 Published online: December 26, 2024 Processing time: 108 Days and 2.9 Hours
Abstract
This article addresses the substantial findings of a study on sodium-dependent glucose transporter 2 inhibitors (SGLT2is) and their effects on myocardial function in patients with type 2 diabetes and asymptomatic heart failure. The editorial explores the broader implications of the study findings for clinical practice, thus highlighting the pivotal role of SGLT2is in improving cardiac function, reducing oxidative stress, and attenuating inflammation. It emphasizes the importance of early intervention with SGLT2is in preventing the progression of diabetic cardiomyopathy; hence, these inhibitors have the potential to transform the management of asymptomatic heart failure in patients with diabetes.
Core Tip: This article emphasizes the clinical importance of sodium-dependent glucose transporter 2 inhibitors (SGLT2is) in managing myocardial function for patients with type 2 diabetes and asymptomatic heart failure. By improving cardiac function, reducing oxidative stress, and lowering inflammation, SGLT2is present a promising therapeutic strategy. Early intervention with SGLT2is can prevent the progression of diabetic cardiomyopathy, highlighting their transformative potential in the treatment of asymptomatic heart failure in patients with diabetes.
